45 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
12
Ending by 2030
Jan 2030
Next term end
17
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2030 · Medium confidence
Also notable
Ends Jun 2033 · High confidence
Also notable
Ends May 2036 · High confidence
Posterior Segment Drug Delivery
US 8,399,006
The most cited patent in this portfolio, cited by 191 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Injector Apparatus and Method for Drug Delivery
US 11,786,396
Cited by 22 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2033.
Ocular Implant Delivery Device and Method
US 11,337,853
Cited by 12 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 20 to 30, 2026 · next Dec 20
- 1 fee due Jan 30, 2027The maintenance fee for Stable and Soluble Formulations of Receptor Tyrosine Kinase Inhibitors, and Methods of Preparation Thereof (US 10,363,255) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 2 fees due Mar 3, 2027
- 1 fee due Apr 17, 2027The maintenance fee for Injector Apparatus and Method for Drug Delivery (US 11,786,396) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Diagnostic Methods and Apparatus (US 11,813,196) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Expandable Drug Delivery Devices and Methods of Use (US 10,500,091) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Insertion and Removal Methods and Apparatus for Therapeutic Devices (US 10,603,209) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Combined Drug Delivery Methods and Apparatus (US 10,617,557) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 17 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Posterior Segment Drug Delivery | 12 in force | to Jan 2030 |
| Injector Apparatus and Method for Drug Delivery | 5 in force | to Jun 2033 |
| Expandable Drug Delivery Devices and Methods of Use | 3 in force | to Nov 2037 |
| Ocular Implant Delivery Device and Method | 3 in force | to May 2036 |
| Ophthalmic Implant for Delivering Therapeutic Substances | 3 in force | to Sep 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,656,152 | Posterior Segment Drug Delivery In force · Medium confidence | In force | Medium confidence | |
| US 10,813,788 | Implantable Therapeutic Device In force · Medium confidence | In force | Medium confidence | |
| US 11,642,310 | Posterior Segment Drug Delivery In force · Medium confidence | In force | Medium confidence | |
| US 8,277,830 | Posterior Segment Drug Delivery In force · Medium confidence | In force | Medium confidence | |
| US 8,298,578 | Posterior Segment Drug Delivery In force · Medium confidence | In force | Medium confidence | |
| US 8,399,006 | Posterior Segment Drug Delivery In force · Medium confidence | In force | Medium confidence | |
| US 8,623,395 | Implantable Therapeutic Device In force · Medium confidence | In force | Medium confidence | |
| US 8,795,712 | Posterior Segment Drug Delivery In force · Medium confidence | In force | Medium confidence | |
| US 8,808,727 | Posterior Segment Drug Delivery In force · Medium confidence | In force | Medium confidence | |
| US 9,066,779 | Implantable Therapeutic Device In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 45: 1 patent in force now held by others · 3 patents ended · 7 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.